Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) gapped up before the market opened on Monday after Chardan Capital raised their price target on the stock from $4.00 to $5.00. The stock had previously closed at $8.67, but opened at $8.69. Chardan Capital currently has a sell rating on the stock. Achillion Pharmaceuticals shares last traded at $8.37, with a volume of 1,255,058 shares traded.
A number of other research firms have also commented on ACHN. Robert W. Baird restated an “outperform” rating and set a $10.00 price target on shares of Achillion Pharmaceuticals in a research report on Monday, June 6th. FBR & Co started coverage on Achillion Pharmaceuticals in a research report on Thursday, September 15th. They issued an “outperform” rating and a $16.00 price objective on the stock. Leerink Swann reiterated a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Sunday, June 12th. JMP Securities upgraded Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $13.00 price objective on the stock in a research report on Thursday, July 7th. Finally, Wedbush started coverage on Achillion Pharmaceuticals in a research report on Thursday, September 22nd. They issued an “outperform” rating and a $13.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. Achillion Pharmaceuticals has an average rating of “Hold” and a consensus price target of $10.70.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Fund Advisors increased its position in Achillion Pharmaceuticals by 2.3% in the first quarter. BlackRock Fund Advisors now owns 4,573,313 shares of the biopharmaceutical company’s stock worth $35,306,000 after buying an additional 102,179 shares during the period. HBK Investments L P bought a new position in Achillion Pharmaceuticals during the first quarter worth $455,000. Schonfeld Strategic Advisors LLC bought a new position in Achillion Pharmaceuticals during the first quarter worth $101,000. Swiss National Bank increased its position in Achillion Pharmaceuticals by 1.9% in the second quarter. Swiss National Bank now owns 189,100 shares of the biopharmaceutical company’s stock worth $1,475,000 after buying an additional 3,600 shares during the period. Finally, Columbus Circle Investors increased its position in Achillion Pharmaceuticals by 46.0% in the second quarter. Columbus Circle Investors now owns 110,174 shares of the biopharmaceutical company’s stock worth $859,000 after buying an additional 34,720 shares during the period. 79.43% of the stock is currently owned by institutional investors.
The company has a market cap of $1.13 billion, a P/E ratio of 168.37 and a beta of 2.21. The firm’s 50-day moving average price is $8.44 and its 200-day moving average price is $8.44.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. During the same quarter last year, the company earned ($0.25) earnings per share. On average, analysts forecast that Achillion Pharmaceuticals Inc. will post ($0.61) earnings per share for the current year.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.